Xeris Biopharma Holdings Inc (NASDAQ:XERS) has a beta value of 1.09 and has seen 1.82 million shares traded in the recent trading session. The company, currently valued at $799.72M, closed the recent trade at $5.20 per share which meant it lost -$0.29 on the day or -5.37% during that session. The XERS stock price is -16.73% off its 52-week high price of $6.07 and 67.5% above the 52-week low of $1.69. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.48 million shares traded. The 3-month trading volume is 2.62 million shares.
The consensus among analysts is that Xeris Biopharma Holdings Inc (XERS) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.04.
Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information
Sporting -5.37% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the XERS stock price touched $5.20 or saw a rise of 14.33%. Year-to-date, Xeris Biopharma Holdings Inc shares have moved 53.24%, while the 5-day performance has seen it change -11.50%. Over the past 30 days, the shares of Xeris Biopharma Holdings Inc (NASDAQ:XERS) have changed 40.79%. Short interest in the company has seen 11.21 million shares shorted with days to cover at 3.4.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could drop -4.0% from the levels at last check today. The projected low price target is $4.0 while the price target rests at a high of $6.6. In that case, then, we find that the latest price level in today’s session is -26.92% off the targeted high while a plunge would see the stock lose 23.08% from the levels at last check today.
Xeris Biopharma Holdings Inc (XERS) estimates and forecasts
The company’s shares have gained 81.01% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 29.17%.
6 analysts offering their estimates for the company have set an average revenue estimate of 57.61M for the current quarter. 6 have an estimated revenue figure of 62.65M for the next ending quarter. Year-ago sales stood 40.64M and 48.06M respectively for this quarter and the next, and analysts expect sales will grow by 41.76% for the current quarter and 29.17% for the next. If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 40.01% over the past 5 years.
XERS Dividends
Xeris Biopharma Holdings Inc is expected to release its next earnings report on 2025-Mar-05 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s Major holders
Insiders own 3.97% of the company shares, while shares held by institutions stand at 42.81% with a share float percentage of 44.58%. Investors are also buoyed by the number of investors in a company, with Xeris Biopharma Holdings Inc having a total of 201.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 10.33 million shares worth more than $23.25 million. As of 2024-06-30, BLACKROCK INC. held 6.9649% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 7.66 million shares as of 2024-06-30. The firm’s total holdings are worth over $17.23 million and represent 5.4492% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 2.74% shares in the company for having 4.22 shares of worth $21.97 million while later fund manager owns 3.58 shares of worth $18.64 million as of Feb 28, 2025, which makes it owner of about 2.33% of company’s outstanding stock.
